Ravi Salgia to Prospective Studies
This is a "connection" page, showing publications Ravi Salgia has written about Prospective Studies.
Connection Strength
0.147
-
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 09 07; 28(9):e748-e755.
Score: 0.032
-
An Updated Review on Radiation Treatment Management in Thymus Cancers. Clin Lung Cancer. 2022 Nov; 23(7):561-570.
Score: 0.029
-
Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022 08; 173:10-18.
Score: 0.029
-
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217.
Score: 0.025
-
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
Score: 0.015
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.014
-
Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med. 1989 Sep; 149(9):1959-61.
Score: 0.003